Press release
Lawsuit filed for Investors who lost money with shares of AstraZeneca PLC (NASDAQ: AZN)
A lawsuit was filed on behalf of investors in AstraZeneca PLC (NASDAQ: AZN) shares over alleged securities laws violations.
Investors who purchased a significant amount of shares of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, have certain options and for certain investors are short and strict deadlines running. Deadline: February 21, 2025. NASDAQ: AZN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On October 30, 2024, AstraZeneca PLC disclosed that its International Executive Vice President and China President, Leon Wang, was under investigation by Chinese Authorities.
Then, on November 5, 2024, news outlets reported that a fraud investigation linked to AstraZeneca PLC had expanded to several Chinese government agencies, implicating dozens of senior executives at the Company.
Then, on December 18, 2024, Financial Times reported that Wang had been arrested and that AstraZeneca "expect[ed] to see an 'evident' revenue hit in China in the wake of the arrest," stating that "the sales impact is already very evident."
Shares of AstraZeneca PLC (NASDAQ: AZN) declined from $87.68 per share on August 30, 2024, to as low as $62.75 per share on November 18, 2024.
The plaintiff claims that between February 23, 2022 and December 17, 2024, the defendants made materially false and/or misleading statements and/or failed to disclose that AstraZeneca engaged in insurance fraud in China, that as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities, that as a result, AstraZeneca understated its legal risks, that the foregoing, once revealed, could materially harm AstraZeneca's business activities in China, and that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of AstraZeneca PLC (NASDAQ: AZN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of AstraZeneca PLC (NASDAQ: AZN) here
News-ID: 3850036 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for AstraZeneca
Hypereosinophilic Syndrome Market Revenue to Expand Significantly by 2032, State …
The Key Hypereosinophilic Syndrome Companies in the market include - GlaxoSmithKline, AstraZeneca, Novartis, M.D. Anderson Cancer Center, AstraZeneca, and others.
DelveInsight's "Hypereosinophilic Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Hypereosinophilic Syndrome, historical and forecasted epidemiology as well as the Hypereosinophilic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth…
DNA Repair Drugs Market May See a Big Move | Major Giants- AbbVie, AstraZeneca, …
The latest study released on the Global DNA Repair Drugs Market by HTF MI evaluates market size, trend, and forecast to 2030. The DNA Repair Drugs market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key…
Calcium Channel Antagonist Market Will Reflect Significant Growth Prospects By 2 …
The Calcium Channel Antagonist report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research.
Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=7764202
The Calcium…
Nasal Polyposis Market to Witness Growth by (2022-2032), Estimates DelveInsight …
The Nasal Polyposis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nasal Polyposis pipeline products will significantly revolutionize the Nasal Polyposis market dynamics.
DelveInsight's "Nasal Polyposis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nasal Polyposis, historical and forecasted epidemiology as well as the Nasal Polyposis market trends in the…
Global Influenza Vaccines Market: Emerging Trends, Major Key Players Astrazeneca …
According to the report, The global Influenza Vaccines market is expected to grow from $ billion in 2020 to $ billion in 2028 at a CAGR of 15%.
Request Free Sample Report or PDF Copy: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=006954
The latest research report published by Evolve Business Intelligence examines the impacts of numerous market aspects on the global INFLUENZA VACCINES industry including a look at the current market size and forecasts for key segments and…
What's driving the Cannula Market Growth? Prominent Players Merck, AstraZeneca, …
The global cannula market is estimated to grow to USD 222.09 million by 2026 growing at a substantial CAGR during the forecast period of 2019 to 2026. The rise in market value can be factored to the growing preference of minimally invasive surgical procedures from the patients.Global Cannula Market By Product (Vascular Cannula, Cardiac Cannula, Arthroscopy Cannula, Dermatology Cannula, Nasal Cannula, Others), Type (Neonatal, Straight, Winged, Wing with Port, Winged…
